Humanized L243 antibodies

Details Humanized L243 antibodies Humanized L243 antibodies

2006-03-03

2009-11-03

O'Hara, Eileen B (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S391700, C530S391300, C530S388220

Reexamination Certificate

active

07612180

ABSTRACT:
Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6187287 (2001-02-01), Leung et al.
patent: 6730300 (2004-05-01), Leung et al.
patent: 7022500 (2006-04-01), Queen et al.
patent: 2003/0103979 (2003-06-01), Leung et al.
Altomonte et al. “Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma.” J Cell Physiol. 2004;200:272-276.
Aoudjit et al. “HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.” Exp Cell Res. 2004;299:79-90.
ATCC Deposit HB55.
Blancheteau et al. “HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases.” Hum Immunol. 2002;63:375-383.
Bridges et al. “Selective in vivo antitumor effects of monoclonal anti-I-A antibody on a B lymphoma.” J Immunol. 1987;139:4242-4249.
Brozek et al. “Anti-DR antibodies inhibit in vitro production of human rheumatoid factor.” J Clin Lab Immunol. 1990;31:105-109.
Elsasser et al. “HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.” Blood 1996;87:3803-3812.
Fu et al. “HLA-DR alpha chain residues located on the outer loops are involved in non-polymorphic and polymorphic antibody-binding epitopes.” Hum Immunol. 1994; 39:253-260.
Gussow et al. “Humanization of monoclonal antibodies.” Method Enzymol. 203:99-121, (1991).
Kabelitz et al. “Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.” Cell Immunol. 1989;120:21-30.
Lampson et al. “Two populations of la-like molecules on a human B cell line.” J. Immunol. (1980) 125:293-299.
Lund et al. “Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I.” Eur. J. Biochem. Dec. 2000. vol. 267, No. 24, pp. 7246-7257.
Nagy et al. “Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.” Nat Med. 2002;8:801-807.
Stein et al. “Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.” Blood 2006;108:2736-44.
Vaswani et al.“Humanized antibodies as potential therapeutic drugs.” Ann. Allergy Asthma Immunol. 1998;81:105-119.

Affiliated with

Also associated with

Rating

Humanized L243 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanized L243 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized L243 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4085378